Amendment Agreement
|
Certain confidential information contained in this document, marked by [***], has been omitted because such information is both not material and is the type that
the Company customarily and actually treats that as private or confidential.
|
Exhibit 10.8
|
| Amendment Agreement |
This Amendment Agreement (the “Agreement”) is entered into as indicated below, among the National Institutes for Quantum and Radiological Science and Technology (“QST”), a research institute in Japan, having an address at 0-0-0 Xxxxxxx, Xxxxx-xx, Xxxxx-xxx, Xxxxx 263-8555, Japan, APRINOIA Therapeutics Inc. (“APRINOIA TW”), a corporation of Taiwan, having an address at 00X., Xx.0, Xxxx Xx., Xxxxxxx Xxxx., Xxxxxx Xxxx 00000, Xxxxxx (which is migrated from 17F., Xx.000, Xxx. 0, Xxxxxxxxx X. Xx., Xx-xx Xxxx., Xxxxxx Xxxx 000, Xxxxxx (R.O.C.) on January 16th, 2017) and APRINOIA Therapeutics Inc. (“APRINOIA KY”), a corporation of Cayman Islands, having an address at The Grand Pavilion Commercial Centre, Oleander Way, 000 Xxxx Xxx Xxxx, X.X. Box 32052, Grand Cayman KY1-1208, Cayman Islands, in consideration of the mutual agreement to make alterations to the Exclusive License Agreement (the “Original Agreement”) executed on October 20th, 2016 by QST and APRINOIA TW.
1. DEFINITIONS
Unless otherwise agreed in the Agreement, the terms used in this Agreement shall adhere to the definitions in the Original Agreement.
2. CHANGE OF THE PARTIES
This Agreement shall change the term for APRINOIA being a party to the Original Agreement, as provided below:
| Before | APRINOIA Therapeutics Inc. (“APRINOIA”), a corporation of Taiwan, having an address at 00X., Xx.000, Xxx. 0, Xxxxxxxxx X. Xx., Xx-xx Xxxx., Xxxxxx Xxxx 000, Xxxxxx (R.O.C.) |
| After | APRINOIA Therapeutics Inc. (“APRINOIA”), a corporation of Cayman Islands, having an address at The Grand Pavilion Commercial Centre, Oleander Way, 000 Xxxx Xxx Xxxx, X.X. Box 32052, Grand Cayman KY1-1208, Cayman Islands |
The addressee in notices defined under section19 of the Original Agreement shall be changed as provided below:
| Before |
To APRINOIA: Attention: Xxxx-Xxxx Xxxx, Ph.D 17F., Xx.000, Xxx. 0, Xxxxxxxxx X. Xx., Xx’xx Xxxx., Xxxxxx Xxxx 000, Xxxxxx |
| After |
To APRINOIA: Attention: Xxxx-Xxxx Xxxx, Ph.D 00X., Xx.0, Xxxx Xx., Xxxxxxx Xxxx., Xxxxxx Xxxx 00000, Xxxxxx |
3. GENERAL
| 3.1 | This Agreement shall become effective as of January 11th, 2018. |
| 3.2 | This Agreement is drafted in both English and Japanese. If there is any discrepancy between the English and Japanese versions, the English version shall prevail. |
| 3.2 | Except as expressly provided for alterations herein, the provisions in the Original Agreement shall remain in effect. |
In witness whereof, APRINOIA TW, APRINOIA KY and QST have executed this Agreement in three (3) originals by its duly authorized officer or representative.
National Institutes for Quantum and Radiological Science and Technology (QST)
Representative: XXXXXX Xxxxxx
Title: President
Address: 0-0-0 Xxxxxxx, Xxxxx-xx, Xxxxx-xxx, Xxxxx 000-0000, Xxxxx
| Signature: | /s/ XXXXXX Xxxxxx |
| Date: | 2018.1.11. |
APRINOIA Therapeutics Inc. (APRINOIA TW)
Representative: Xxxx-Xxxx Xxxx, Ph.D.
Title: Cheif Executive Officer
Address: 00X., Xx.0, Xxxx Xx., Xxxxxxx Xxxx., Xxxxxx Xxxx 00000, Xxxxxx
| Signature: | /s/ Xxxx-Xxxx Xxxx, Ph.D. |
| Date: | Jan 11 2018 |
APRINOIA Therapeutics Inc. (APRINOIA KY)
Representative: Xxxx-Xxxx Xxxx, Ph.D.
Title: Chairman
Address: The Grand Pavilion Commercial Centre, Oleander Way, 000 Xxxx Xxx Xxxx, X.X. Box 32052, Grand Cayman KY1-1208, Cayman Islands
| Signature: | /s/ Xxxx-Xxxx Xxxx, Ph.D. |
| Date: | Jan 11 2018 |
3
